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Abstract
Background. Lymph node involvement in periampullary malignancy is the single most important factor in predicting
survival in pancreaticoduodenectomy (PD). The role of nodal sampling in PD has not been well evaluated. This study
evaluates the utility of nodal sampling of nodal stations 8 and 12, which are easily dissected early in PD, in overall final nodal
status. Patients and methods. Fifty patients underwent PD at a single institution by a one surgeon over a 15 month period.
Nodal stations 8 and 12 were sent separately for pathologic evaluation. Twenty-eight patients had a final diagnosis of
periampullary malignancy. Demographic and pathologic data were collected retrospectively from patient charts. Positive
and negative predictive values of nodes 8 and 12 were evaluated. Results. Eighteen of 28 patients with a diagnosis of
periampullary malignancy had pathologically negative nodes 8 and 12, and a final nodal status (all peripancreatic lymph
nodes) negative for nodal involvement. Nine of 28 patients had a negative nodal sampling result, but a positive final nodal
status for metastatic tumor. The remaining four patients had both positive nodal sampling and final nodal status for
metastatic tumor. The negative predictive value of negative nodes 8 and 12 was 0.625. Conclusion. The negative predictive of
a negative node 8 and 12 of 0.625 suggests that the decision to proceed with or abort PD should not be based on
intraoperative evaluation of these nodes. Performance of PD should be undertaken if technically feasible, and not based on
intraoperative nodal assessment.
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Introduction
Pancreaticoduodenectomy (PD) remains the surgical
procedure of choice in patients with a diagnosis
of periampullary malignancy. In recent years, several
high volume centers with significant expertise have
reported an operative mortality of B 5% for PD [17],
which has been linked to many factors including the
hospital volume [8]. Indeed, our center is one such
high volume center, and we have previously reported a
mortality rate of 2.2% [9].
Although perioperative mortality has decreased
significantly, the long-term survival of patients under-
going PD for malignant periampullary tumors re-
mains poor. Lymph node involvement has
consistently been considered one of the poor prog-
nostic factors in long-term survival [1012], although
it has not been used as a definitive indicator for
selection of treatment. From a technical standpoint,
the initial step in PD is evaluation of resectability. In
past decades, peripancreatic lymph node involvement
has been considered an absolute sign of unresect-
ability [13] and surgeons have used this criterion as a
reason to abandon the procedure. Intraoperative
assessment of easily accessible lymph nodes is used
by some surgeons to assess the extent of disease and
decide on whether to proceed with PD.
The aim of this study was to evaluate the predictive
value of nodal sampling of easily accessible nodes
(stations 8 and 12 in the Japanese staging system [14])
on final nodal status in patients with a diagnosis of
periampullary malignancy. The hypothesis is that
nodal sampling is not predictive of final nodal status
in PD and therefore should not dictate the decision to
proceed with or abandon the resection.
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Patients and methods
Patients who underwent a PD and had a confirmed
histologic diagnosis of periampullary malignancy were
included in this study. Of the 50 consecutive patients
who underwent PD by a single surgeon between
September 2005 and November 2006, 31 patients
qualified for this study. Six patients with a final
diagnosis of chronic pancreatitis, 3 with duodenal/
ampullary adenoma, and 10 with a diagnosis of
intraductal papillary mucinous neoplasm of the pan-
creas (IPMN) were excluded. Nodes were sent to
pathology separately in a prospective manner. How-
ever, clinical and pathologic characteristics of patients
were obtained by retrospective review of electronic
medical records and paper charts. The protocol was
approved by the Institutional Review Board at the
Methodist Dallas Medical Center.
All patients underwent a pylorus-preserving PD
unless there was concern regarding margin status of
the specimen or duodenal ischemia. Routine duo-
deno- or gastro-jejunostomy, duct-to-mucosa pan-
creatic and biliary drainage were performed in all
patients. During the portal nodal dissection, nodal
group 8 (common hepatic artery nodal group) and 12
(hepatoduodenal nodal group) according to the Japan
Pancreas Society classification of peripancreatic
lymph node groups, were routinely sent to pathology
(see Figure 1). These nodes were reported separately
from the other nodes obtained en bloc with the
specimen in the final pathology report as positive or
negative for metastatic carcinoma.
The following data were analyzed: (1) demo-
graphics and preoperative data including co-morbid-
ities, (2) final pathologic diagnosis, and (3) tumor
characteristics including the margin status and lym-
phatic, vascular, and perineural invasion.
To evaluate the predictive value, patients were
divided into three groups based on the results of
nodal sampling and final nodal status for metastatic
carcinoma. Group 1 had negative nodal sampling and
also final nodal status for carcinoma. Group 2 had
negative nodal sampling but positive nodal status for
metastatic carcinoma. Group 3 had positive results for
both nodal sampling and final nodal status.
Negative and positive predictive value of nodal
sampling and prediction of final nodal status was
calculated for negative and positive nodal sampling
results, respectively. Statistical analysis was performed
using the Fisher’s exact test comparing the overall
node positive group to the regional node (nodes 8 and
12) positive group.
Results
Patient demographics are shown in Table I. There
were a total of 31 consecutive patients with a diagnosis
of periampullary malignancy who underwent PD. The
median age was 68 years with a range of 2785 years.
There were twenty (64%) females. Eighteen (58%)
patients had a diagnosis of hypertension preopera-
tively. Nine (29%) patients had diabetes, seven
(22.5%) had coronary artery disease, and three
(9.6%) had a history of myocardial infarction. Three
(9.6%) patients had chronic obstructive pulmonary
disease (COPD) and one patient each had a diagnosis
of congestive heart failure (CHF), peripheral vascular
disease, and peptic ulcer disease.
Pathologic diagnoses of all patients who underwent
PD and were included in this study are shown in
Table II. There were a total of 27 (87%) patients with
a diagnosis of periampullary malignancy. Of these, 17
(62.9%) had pancreatic adenocarcinoma as the final
pathologic diagnosis and 5 (18.5%) had a diagnosis of
ampullary adenocarcinoma. There were two (4.5%)
patients with a diagnosis of distal bile duct adenocar-
cinoma and three (11.1%) with a diagnosis of
Figure 1. Illustration of nodes 8 and 12 in the Japanese classifica-
tion system. This illustration shows node 8 (above the hepatic
artery) and node 12 (lateral to the common bile duct) in relation to
the portal structures.
Table I. Demographics of patients undergoing PD for malignant
periampullary tumors.
Parameter Value
Age (years), median (range) 68 (2785)
Gender
Male 11 (36)
Female 21 (64)
Past medical history
Hypertension 18 (58)
Asthma 1 (3.2)
Congestive heart failure (CHF) 1 (3.3)
Diabetes mellitus 9 (29)
Coronary artery disease (CAD) 7 (22.5)
Myocardial infarction (MI) 3 (9.6)
Peripheral vascular disease 1 (3.2)
Chronic obstructive pulmonary disease (COPD) 3 (9.6)
Peptic ulcer disease 1 (3.2)
The table shows demographic data for patients undergoing PD at
our tertiary care community hospital. Values are n (%) unless
otherwise specified.
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duodenal adenocarcinoma. We also included one
(3.2%) patient with a neuroendocrine cancer, two
(6.4%) patients with a cystadenoma/cystadenocarci-
noma, and one patient with a solid pseudopapillary
tumor.
Tumor characteristics and nodal status of patients
included in this study are shown in Table III. There
were 20 (64.5%) with a negative margin and 11
(35.5%) with a positive margin. The SMA margin was
the most frequently positive margin. It is interesting
that SMA positivity has increased since the operating
surgeon orients and inks this margin specifically for
the pathologist. Specific sections are submitted from
the inked margin. Eighteen (58%) patients had a
negative final nodal status and 13 (41.9%) had a
positive nodal status in the final pathology. Lymphatic
invasion was seen in 12 (38.7%) and 19 (61.2%) had
no evidence of lymphatic invasion. Perineural invasion
was seen in 15 patients (48.3%) and was absent in 16
(51.6%). Microscopic vascular invasion was identified
in four patients (12.9%).
The predictive value of nodal groups 8 and 12 in
prediction of overall nodal status of patients is shown
in Table IV. Patients with borderline tumors (n3)
were excluded from this analysis. Fifteen patients had
a negative nodal sampling of groups 8 and 12 and also
had a negative final nodal status for metastatic
adenocarcinoma. The second group, which included
nine patients, had a negative nodal sampling for
groups 8 and 12, but had a positive nodal status in
the final pathology report. Therefore, the negative
predictive value of nodal sampling in prediction of
final nodal status for metastatic adenocarcinoma was
0.625 (95% confidence interval (CI) 0.140.50). The
third and final group included four patients that were
positive on both nodal sampling and final nodal status
results for metastatic adenocarcinoma. The positive
predictive value of nodal sampling in prediction of
final nodal status for metastatic adenocarcinoma was
1.0 by definition. The difference between the groups
that were node-positive on overall evaluation com-
pared with the group that was regionally node-positive
(nodes 8 and 12) was statistically significant by the x2
test (p0.035).
Discussion
This study examining the predictive value of nodal
sampling on final nodal status suggests that intrao-
perative assessment of nodal groups 8 and 12 is not
warranted. The data presented here would support
the decision to perform PD without interruption of
the surgery for intraoperative nodal evaluation. While
this may seem obvious to experienced pancreatic
surgeons, this analysis will encourage those surgeons
who may not be so experienced to proceed with PD
without the added time and expense of submitting
nodes for frozen section nodal analysis.
Herein we have reported our data on the predictive
value of nodal sampling of group 8 and 12 in
predicting the overall nodal status in patients with a
diagnosis of malignant periampullary tumor. In recent
years, there has been increasing interest regarding the
role of lymphatic involvement in gastrointestinal
malignancies. One of these interesting issues is the
role of nodal sampling and the search for a sentinel
lymph node in gastric and colon cancers [1517].
Similarly the idea of nodal sampling in periampullary
cancer is under active investigation [18,19]. Our data
would suggest that nodes 8 and 12 are not the sentinel
nodes in this disease process.
The first step in operative assessment of periam-
pullary cancer is determination of resectability. In past
decades peripancreatic lymph node involvement was
considered an absolute contraindication to resectabil-
ity. In many cases the concern for perioperative
mortality and morbidity were the factors favoring a
Table II. Pathologic diagnosis of 31 consecutive patients under-
going PD for malignant periampullary tumors.
Diagnosis Value
Periampullary cancer 27 (87)
Pancreas 17 (62.9)
Ampulla 5 (18.5)
Distal bile duct 2 (7.4)
Duodenum 3 (11.1)
Neuroendocrine tumor 1 (3.2)
Cystadenoma/cystadenocarcinoma 2 (6.4)
Solid pseudopapillary tumor 1 (3.2)
The table shows the pathologic diagnosis code for which patients
underwent PD in our series. Values in table are n (%) unless
otherwise specified.
Table III. Nodal status and tumor characteristics in 31 consecutive
patients undergoing PD for malignant periampullary tumors.
Tumor/nodal status Negative Positive
Nodes 18 (58) 13 (41.9)
Margins 20 (64.5) 11 (35.4)
Lymphatic invasion 19 (61.2) 12 (38.7)
Perineural invasion 16 (51.6) 15 (48.3)
Microscopic vascular invasion 27 (87) 4 (12.9)
Thirty-one patients included in this study are shown based on their
pathologic characteristics. Patients are separated into two groups
based on final nodal status.
Table IV. Predictive value of nodal sampling.
Patients Nodal sampling Regional nodal Predictive value
15 Negative Negative 0.625 (NPV)
9 Negative Positive
4 Positive Positive 1 (PPV)
The table shows positive and negative predictive values of group 8
and 12 nodes on final nodal status in 28 consecutive patients
undergoing PD for a malignant periampullary tumor. NPV, negative
predictive value; PPV, positive predictive value.
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conservative approach. Over the past decade, several
studies have shown an improved outcome for PD in
high volume, experienced centers, including our own
[17,9]. Yet the overall survival for periampullary
tumors remains poor [4]. There are many prognostic
factors affecting the long-term survival in these
patients including lymph node metastasis [1012],
tumor differentiation [11], margin status [12], and
tumor size [11,12,20]. Among these factors, lymph
node involvement is one of the most significant
prognostic factors affecting the long-term survival.
Despite the poor prognosis of PD in patients with
nodal involvement, data from high volume centers
suggest that PD can be performed in this subgroup
safely and with some potential benefit [2,13].
To address the issue, we routinely sampled nodal
groups 8 and 12 (based on the classification system of
the Japan Pancreas Society [14]), during our dissec-
tion. These lymphatic groups were selected as they are
easily visualized and biopsied during the standard
dissection. Connor et al. [21] have shown a significant
decrease in survival with the involvement of group 8.
In another recent study [22], involvement of groups 8
and 12 was associated with a significantly poorer
outcome. Interestingly, Maithel et al. recently re-
ported that a common bile duct (CBD) node (group
12) short-axis size of 10 mm in CT scan predicts
tumor unresectability [23]. These data do not provide
insight into the predictive value of these nodes on
overall nodal status.
In our cohort all of 31 consecutive patients with a
diagnosis of periampullary malignancy underwent a
standard resection. The negative predictive value for
prediction of final nodal status was only 0.625,
suggesting that the finding of a negative node 8 and
12 was not a good indicator of a negative final nodal
status. The positive predictive value was 1.00, as
would be expected as positive nodes 8 and 12 would
result in a positive overall nodal status in all patients.
Interestingly, most patients (54%) with a positive final
nodal status also had a positive margin, which also
correlated closely with perineural and lymphatic
invasion.
The question of what to do if there is a known
positive node is challenging and interesting. There are
data to support proceeding with PD if an R0 resection
is possible. Data from France suggests that involve-
ment of greater than two lymph nodes results in a
worse survival [24], a concept that is corroborated by
several international studies suggesting that lymph
node number and ratio may, in fact, be key prognostic
factors [22,25,26]. These data need to be tempered
with the surgeon’s personal experience. We feel that
PD should be performed even in the face of positive
nodal disease if the surgeon can perform the operation
with a reasonably low risk of mortality, and with the
clear understanding of all involved that PD will likely
be non-curative in this patient population.
The extent of the lymph nodal dissection is another
point of controversy. There has been interest in
extended lymph nodal dissection in PD. Surgical
literature from Germany and Japan suggests that
radical nodal dissection does not affect overall survival
and may in fact be associated with an increased risk of
complications [27,28]. Similar conclusions were
reached by several groups in North America [2931]
including a multi-institution randomized study [32].
It is the authors’ preference to perform an ‘anatomi-
cally correct’ dissection; this includes skeletonizing the
vena cave to preserve the posterior capsule to the
pancreatic head (the ‘mesopancreas’), in a similar way
to preserving the mesorectum. We do not make an
additional effort to take aortocaval nodes, but will
visualize both gonadal veins. Similarly, respecting the
arterial structures and keeping in the plane of the
‘glistening vessel’ will result in reasonable portal nodal
clearance.
In conclusion, we have demonstrated that the
intraoperative nodal sampling of groups 8 and 12 is
not an optimal way to predict the final nodal status
and should not be used as treatment selection
criterion. However, the finding of a positive metastatic
focus in nodes 8 and 12 does suggest a more
aggressive disease, as this was correlated with positive
surgical margin status, and lymphatic and perineural
invasion. Overall, it is our recommendation that
intraoperative evaluation of nodes 8 and 12 should
not be routinely performed, as it does not correlate
with final nodal status. PD should be performed when
technically possible based on resectability status and
not nodal evaluation.
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